Aclaris Therapeutics (ACRS) Common Equity (2014 - 2026)

Aclaris Therapeutics' Common Equity history runs 13 years deep, the most recent figure standing at $143.6 million for Q1 2026.

• In Q1 2026, Common Equity changed 0.29% year-over-year to $143.6 million; the TTM figure through Mar 2026 stood at $143.6 million (changed 0.29% YoY), while the FY2025 annual figure was $103.1 million, down 33.73% from the prior year.
• Common Equity was $143.6 million for Q1 2026 at Aclaris Therapeutics, up from $103.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $235.8 million in Q2 2022 to a low of $103.1 million in Q4 2025.
• Historically, Common Equity has averaged $159.3 million across 5 years, with a median of $155.6 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Common Equity soared 60.47% in 2022, then sank 33.73% in 2025.
• A 5-year view of Common Equity shows it stood at $197.6 million in 2022, then dropped by 20.46% to $157.2 million in 2023, then retreated by 1.03% to $155.6 million in 2024, then slumped by 33.73% to $103.1 million in 2025, then soared by 39.35% to $143.6 million in 2026.
• The last three Common Equity figures came in at $143.6 million (Q1 2026), $103.1 million (Q4 2025), and $120.1 million (Q3 2025), per Business Quant data.